Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

janssen-cilag farmacÊutica ltda - golimumabe - antinflamatorios

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

janssen-cilag farmacÊutica ltda - ustequinumabe - imunosupressor

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

libbs farmacÊutica ltda - rituximabe - antineoplasico

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

libbs farmacÊutica ltda - trastuzumabe - antineoplasico

União Europeia - português - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinúria, paroxística - imunossupressores seletivos - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

sanofi medley farmacÊutica ltda. - cloridrato de metoclopramida monoidratado - antiemeticos e antinauseantes

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

alexion servicos e farmaceutica do brasil ltda - ravulizumabe - outros prods nao enquadrados em classe terapeutica especif

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

sandoz do brasil indÚstria farmacÊutica ltda - adalimumabe - antinflamatorios antireumaticos

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

pfizer brasil ltda - trastuzumabe - antineoplasico

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

pfizer brasil ltda - rituximabe - antineoplasicos citotoxicos